HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? (Q73153503)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648572%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

editorial

0 references

title

HER2/neu overexpression: has the Achilles' heel of uterine serous papillary carcinoma been exposed? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648572%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

Alessandro D Santin

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648572%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

publication date

1 March 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648572%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648572%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

volume

88

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648572%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648572%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

page(s)

263-265

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648572%20AND%20SRC:MED&resulttype=core&format=json

Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features

1 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900094-X

7 January 2021

Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900094-X

7 January 2021

Uterine papillary serous carcinoma: patterns of metastatic spread

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900094-X

7 January 2021

Early pathologic stage clear cell carcinoma and uterine papillary serous carcinoma of the endometrium: comparison of clinicopathologic features and survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900094-X

7 January 2021

Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900094-X

7 January 2021

Endometrial papillary serous carcinoma: patterns of spread and treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900094-X

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900094-X

7 January 2021

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900094-X

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900094-X

7 January 2021

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900094-X

7 January 2021

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900094-X

7 January 2021

Flow cytometric measurements of DNA index and S-phase on paraffin-embedded early stage endometrial cancer: an important prognostic indicator

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900094-X

7 January 2021

Loss of p53 function in uterine papillary serous carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900094-X

7 January 2021

Immunohistochemical Evaluation of Estrogen and Progesterone Receptor Content in 183 Patients with Endometrial Carcinoma: Part I: Clinical and Histologic Correlations

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900094-X

7 January 2021

Evaluation of a region on chromosome 1p in ovarian serous carcinoma that is frequently deleted in uterine papillary serous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900094-X

7 January 2021

p27 and cyclin D1 abnormalities in uterine papillary serous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-8258%2802%2900094-X

7 January 2021

10.1016/S0090-8258(02)00094-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12648572%20AND%20SRC:MED&resulttype=core&format=json

1 November 2019

1 reference